Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial
Moleculin released a new CEO Corner video in which Chairman and CEO Walter Klemp discusses progress in the Phase 2/3 MIRACLE trial of Annamycin plus high-dose cytarabine in second-line relapsed or refractory AML. The segment reiterates that Part A enrollment is complete, interim efficacy results are encouraging, and the full 90-patient Part A data readout is anticipated in Q1 2027, with the pivotal Part B expansion to follow. No new clinical data or figures were disclosed; this is investor-communication content that keeps the Q1 2027 readout on the calendar as the near-term catalyst.
Key figures
- Drug Name
- Annamycin (naxtarubicin)
- Phase Of Trial
- Phase 2/3
- Trial name
- MIRACLE (MB-108)
- Data readout
- Q1 2027
- Part a patients
- 90
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.